Скачать или смотреть ChemoCentryx | Avacopan | Who is Drug Avacopan | Drug Tavneos | Uses Tavneos | Side Effect Avacopan

ChemoCentryx | Avacopan | Who is Drug Avacopan | Drug Tavneos | Uses Tavneos | Side Effect Avacopan The FDA has approved Chemo Centryx Inc as an adjunctive avacopan treatment for adults with severe active A N C A associated vasculitis, specifically granulomatosis with polyangiitis and microscopic polyangiitis

Chemo Centryx Inc said the U.S. health agency approved its lead drug for treating a rare, fatal autoimmune disease, sending the biopharmaceutical company's shares up by more than 70%.

The drug, avacopan, which will be available under brand name Tavneos in the next few weeks, will have a wholesale price of between $150,000 and $200,000 per patient per year

Avacopan is an oral C5a receptor antagonist that selectively blocks the effects of C5a thus blocking neutrophil attraction and activation

Avacopan is administered antineutrophil cytoplasmic antibody (A N C A)-associated vasculitides (A A V) - a group of conditions characterized by destruction and inflammation of small blood vessels and affecting different organs, particularly the kidney.

The drug works by blocking the activity of a protein called C5a receptor, which is responsible for causing numerous inflammatory diseases.

Current treatments include immunosuppressants such as Biogen Inc and partner Roche Holding AG's cancer drug Rituxan, combined with daily administration of steroids, which can cause severe side effects.

The disease affects about 40,000 people in the United States, with about 4,000 new cases each year